These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37000552)

  • 41. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
    Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
    J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L; Gow P; Sharples K; Raill B
    Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Up-titration of allopurinol in patients with gout.
    Jennings CG; Mackenzie IS; Flynn R; Ford I; Nuki G; De Caterina R; Riches PL; Ralston SH; MacDonald TM;
    Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial.
    Arroll B; Bennett M; Dalbeth N; Hettiarachchi D; Ben C; Shelling G
    J Prim Health Care; 2009 Dec; 1(4):315-8. PubMed ID: 20690341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors associated with recurrent hospital admissions for gout: a case-control study.
    Hutton I; Gamble G; Gow P; Dalbeth N
    J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 54. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
    Kim JW; Kwak SG; Park SH
    Korean J Intern Med; 2018 Jan; 33(1):228-229. PubMed ID: 28823114
    [No Abstract]   [Full Text] [Related]  

  • 56. Debates in gout management.
    Abhishek A
    Curr Opin Rheumatol; 2020 Mar; 32(2):134-139. PubMed ID: 31842034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
    Stamp LK; Chapman P; Frampton C; Duffull SB; Drake J; Zhang Y; Neogi T
    Rheumatology (Oxford); 2020 Sep; 59(9):2374-2380. PubMed ID: 31891407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The challenges of managing gout in primary care: Results of a best-practice audit.
    Stamp LK; Chapman P; Hudson B; Frampton C; Hamilton G; Judd A
    Aust J Gen Pract; 2019 Sep; 48(9):631-637. PubMed ID: 31476837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
    Feher MD; Hepburn AL; Hogarth MB; Ball SG; Kaye SA
    Rheumatology (Oxford); 2003 Feb; 42(2):321-5. PubMed ID: 12595630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.